Cara Therapeutics, Inc. (0HTC.L)
USD 5.33
(-0.22%)
USD 5.33
(-0.22%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -121.49 Million USD | -38.8% |
| 2022 | -87.53 Million USD | 1.74% |
| 2021 | -89.08 Million USD | -1754.28% |
| 2020 | 5.38 Million USD | 104.82% |
| 2019 | -111.67 Million USD | -44.32% |
| 2018 | -77.38 Million USD | -30.09% |
| 2017 | -59.48 Million USD | -1.86% |
| 2016 | -58.4 Million USD | -131.86% |
| 2015 | -25.18 Million USD | -39.38% |
| 2014 | -18.07 Million USD | -7525.32% |
| 2013 | -237 Thousand USD | 96.2% |
| 2012 | -6.23 Million USD | 34.81% |
| 2011 | -9.56 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -16.21 Million USD | 40.53% |
| 2024 Q1 | -27.26 Million USD | 16.38% |
| 2023 Q3 | -28.03 Million USD | 13.32% |
| 2023 Q1 | -27.65 Million USD | 11.68% |
| 2023 FY | -121.49 Million USD | -38.8% |
| 2023 Q2 | -32.34 Million USD | -16.96% |
| 2023 Q4 | -32.6 Million USD | -16.32% |
| 2022 FY | -87.53 Million USD | 1.74% |
| 2022 Q4 | -31.3 Million USD | -31.29% |
| 2022 Q3 | -23.84 Million USD | -433.21% |
| 2022 Q2 | -4.47 Million USD | 83.98% |
| 2022 Q1 | -27.91 Million USD | 16.74% |
| 2021 Q4 | -33.52 Million USD | -2882.38% |
| 2021 Q2 | -30.87 Million USD | -31.05% |
| 2021 FY | -89.08 Million USD | -1754.28% |
| 2021 Q1 | -23.56 Million USD | -130.09% |
| 2021 Q3 | -1.12 Million USD | 96.36% |
| 2020 Q4 | 78.29 Million USD | 559.99% |
| 2020 Q3 | -17.02 Million USD | 34.25% |
| 2020 Q2 | -25.88 Million USD | 13.72% |
| 2020 Q1 | -30 Million USD | -0.1% |
| 2020 FY | 5.38 Million USD | 104.82% |
| 2019 Q1 | -23.13 Million USD | -5.26% |
| 2019 FY | -111.67 Million USD | -44.32% |
| 2019 Q2 | -24.14 Million USD | -4.36% |
| 2019 Q3 | -34.43 Million USD | -42.63% |
| 2019 Q4 | -29.97 Million USD | 12.96% |
| 2018 FY | -77.38 Million USD | -30.09% |
| 2018 Q4 | -21.97 Million USD | -7.37% |
| 2018 Q3 | -20.46 Million USD | -14.9% |
| 2018 Q2 | -17.81 Million USD | -4.02% |
| 2018 Q1 | -17.12 Million USD | -17.52% |
| 2017 Q3 | -12.95 Million USD | -34.5% |
| 2017 Q2 | -9.63 Million USD | 56.85% |
| 2017 Q4 | -14.57 Million USD | -12.47% |
| 2017 Q1 | -22.32 Million USD | -0.04% |
| 2017 FY | -59.48 Million USD | -1.86% |
| 2016 Q2 | -13.32 Million USD | -21.3% |
| 2016 FY | -58.4 Million USD | -131.86% |
| 2016 Q4 | -22.31 Million USD | -89.54% |
| 2016 Q3 | -11.77 Million USD | 11.65% |
| 2016 Q1 | -10.98 Million USD | -12.92% |
| 2015 Q3 | -5 Million USD | 12.61% |
| 2015 Q2 | -5.73 Million USD | -21.49% |
| 2015 Q1 | -4.71 Million USD | -8.81% |
| 2015 FY | -25.18 Million USD | -39.38% |
| 2015 Q4 | -9.72 Million USD | -94.23% |
| 2014 Q1 | -3.42 Million USD | -62.52% |
| 2014 Q3 | -6.6 Million USD | -77.88% |
| 2014 Q4 | -4.33 Million USD | 34.33% |
| 2014 FY | -18.07 Million USD | -7525.32% |
| 2014 Q2 | -3.71 Million USD | -8.51% |
| 2013 Q2 | 6.91 Million USD | 558.21% |
| 2013 Q4 | -2.1 Million USD | 40.55% |
| 2013 Q1 | -1.51 Million USD | 14.64% |
| 2013 FY | -237 Thousand USD | 96.2% |
| 2013 Q3 | -3.54 Million USD | -151.18% |
| 2012 FY | -6.23 Million USD | 34.81% |
| 2012 Q4 | -1.76 Million USD | -51.85% |
| 2012 Q3 | -1.16 Million USD | 0.0% |
| 2011 FY | -9.56 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 28.186% |
| Dynavax Technologies Corporation | -37.02 Million USD | -228.117% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.137% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -2205.846% |
| Perrigo Company plc | 151.9 Million USD | 179.984% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 55.981% |
| Illumina, Inc. | -1.06 Billion USD | 88.635% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 101.771% |
| Nektar Therapeutics | -137.42 Million USD | 11.592% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 73.62% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 106.145% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -9.836% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -172.002% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 162.484% |
| Waters Corporation | 817.67 Million USD | 114.859% |
| Biogen Inc. | 1.29 Billion USD | 109.369% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 55.66% |
| Adicet Bio, Inc. | -152.03 Million USD | 20.089% |
| Evolus, Inc. | -49.23 Million USD | -146.776% |
| bluebird bio, Inc. | -244.26 Million USD | 50.26% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -24.793% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 21.9% |
| FibroGen, Inc. | -281.81 Million USD | 56.888% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 109.0% |
| Homology Medicines, Inc. | -48.25 Million USD | -151.777% |
| Geron Corporation | -193.94 Million USD | 37.356% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 56.943% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -169.526% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -65.313% |
| Myriad Genetics, Inc. | -123.7 Million USD | 1.783% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 103.002% |
| OPKO Health, Inc. | -157.02 Million USD | 22.625% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -20.498% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 76.422% |
| Zoetis Inc. | 3.06 Billion USD | 103.959% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -152.064% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 111.174% |
| Exelixis, Inc. | 170.88 Million USD | 171.098% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 102.821% |
| uniQure N.V. | -282.87 Million USD | 57.049% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -210.308% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -117.905% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 47.592% |
| Verastem, Inc. | -92.08 Million USD | -31.939% |
| Imunon, Inc. | -21.03 Million USD | -477.71% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 65.653% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 54.636% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 148.424% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 213.248% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 135.991% |
| TG Therapeutics, Inc. | 20.63 Million USD | 688.838% |
| Blueprint Medicines Corporation | -486.27 Million USD | 75.015% |
| Insmed Incorporated | -709.62 Million USD | 82.879% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 68.966% |
| Incyte Corporation | 620.52 Million USD | 119.579% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 83.274% |